Trials / Completed
CompletedNCT03545035
Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 104 (actual)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study aims at obtaining more in-depth information on how patients with chronic lymphocytic leukemia treated with idelalisib and rituximab react to treatment.
Detailed description
This cohort study will recruit patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab between 01/07/2014 and 31/05/2017 at European centres adhering to the GIMEMA group and the ERIC group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | idelalisib and rituximab | patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab |
Timeline
- Start date
- 2019-02-06
- Primary completion
- 2020-10-28
- Completion
- 2020-10-28
- First posted
- 2018-06-04
- Last updated
- 2022-05-12
Locations
38 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT03545035. Inclusion in this directory is not an endorsement.